NovoCure Reports Strong Preliminary Q4/FY25 Results, Repays $561M Debt, and Outlines Key 2026 Milestones

summarizeSummary

NovoCure announced preliminary Q4 and full-year 2025 financial results, highlighting 8% revenue growth and a robust cash position after repaying $561 million in convertible notes, alongside significant operational and regulatory updates for 2026.

check_boxKey Events

• Preliminary Financial Results

  NovoCure reported preliminary full-year 2025 net revenues of $655.4 million and fourth-quarter net revenues of $174.4 million, both representing an 8% increase over the prior year/period.

• Significant Debt Repayment

  The company repaid $561 million of convertible notes at maturity in November 2025, maintaining a strong cash position of $448.3 million as of December 31, 2025.

• Operational Growth

  Global active patients on TTFields therapy reached 4,620, with Optune Gio prescriptions increasing by 6% and active patients by 9% compared to Q4 2024.

• Strategic Leadership and Regulatory Progress

  Frank Leonard was appointed CEO, and the company submitted the final module of its PMA application to the FDA for TTFields therapy for brain metastases from NSCLC.

auto_awesomeAnalysis

NovoCure's preliminary financial results for Q4 and full-year 2025 indicate continued revenue growth and operational strength, with active patient numbers increasing. The most significant aspect of this report is the repayment of $561 million in convertible notes, which substantially de-risks the company's balance sheet and demonstrates strong liquidity. This financial stability, combined with an internal CEO appointment and a clear roadmap of upcoming clinical trial data readouts and FDA decisions in 2026, positions NovoCure for potential future growth and expansion of its Tumor Treating Fields therapy. Investors should monitor the final audited results and the progress of the announced regulatory and clinical milestones.